In vitro, FATP2-deficient neutrophils show low ability to suppress T-cell proliferation, and lipofermata, a FATP2-inhibitor, reduced tumor growth and increases sensitivity to anti-CTLA-4 immunotherapy. This evidence concerns the gene SLC27A2 and neoplasm.